Can accessory breast tissue come back after surgery?

Can accessory breast tissue come back after surgery?

Op. Dr. Mert Demirel explains long-term stability, hormonal changes, and why biology cannot be frozen.

No operation freezes a body in place. The skin keeps adapting, fat keeps responding to weight and hormones, and the years quietly continue to do their work — with or without a surgical history. So when a patient asks whether accessory breast tissue can “come back,” the question is rarely the simple yes‑or‑no it appears to be. Underneath it sit three different concerns: a biological one, a technical one, and a temporal one.

Much of the confusion comes from a single word. Recurrence is used loosely in clinics, brochures, and online forums, and it is asked to cover events that are not the same. True regrowth of glandular tissue, normal fat behaviour, and the slow evolution of the skin envelope all get grouped under the same label — even though they have different causes, different probabilities, and different answers. Calling them by the same name is the first mistake; planning for them as if they were the same is the second.

The more useful question is not “will it come back?” but “under what conditions does this result remain stable, and what changes lie outside the surgeon’s hands?” That reframing sets the rest of the conversation. This article explains what recurrence actually means in this context, what determines the long‑term stability of the result, and how to think about the time horizon of an operation that interacts with weight, hormones, and aging.

What “recurrence” actually means

The word recurrence gets used loosely. In a clinical conversation, three different events tend to be grouped under the same label, and they are not the same thing.

1. True glandular regrowth — actual breast‑type tissue returning in the axilla. When the glandular component has been correctly identified and excised, this is uncommon. Glandular tissue does not regenerate in the way fat can. The patients in whom it does occur often had an incomplete excision the first time, or had a procedure that was never designed to address the glandular component at all.

2. Change in the surrounding fat. The axillary region contains fibrofatty tissue that may not have been the primary target of the operation. That fat behaves like fat anywhere else on the body — it expands and contracts with weight. A patient who gains a meaningful amount of weight after surgery may notice fullness returning to the area, even though the original glandular tissue is gone. This is not regrowth; it is fat behaving as fat.

3. Envelope evolution. Skin is a living tissue. Pregnancy, breastfeeding, hormonal therapy, weight change, and aging all influence how the skin envelope sits over the underlying contour. A small fold that was not present at six months may appear at five years. The original surgical result was correct; biology has simply continued.

The dominant driver of what patients call “recurrence” is almost always one of these last two — fat or envelope — not the first.

What each scenario changes (and what it cannot change)

Once we separate the three events, the conversation about prevention and management becomes more honest.

• A complete glandular excision done at the time of the original operation is the strongest protection against true regrowth. The trade‑off is a slightly larger operation, and — in some patients — a small scar that must be justified. This approach is for patients in whom the glandular component is the dominant tissue.

• A liposuction‑only contouring approach has a different trade‑off profile. It avoids a visible scar, recovery is shorter, and the contour gain can be excellent in the right candidate. But if there was glandular tissue mixed into the area, liposuction does not reliably address it, and what looks like “recurrence” later may simply be tissue that was never removed in the first place. This option is for patients with predominantly fatty tissue and good skin recoil.

• A staged approach is sometimes the most realistic plan. Address the primary driver first, then re‑evaluate the area at six to twelve months, and consider a small refinement only if it is genuinely needed. Doing less, well, is usually better than doing more, hopefully.

Before committing to a plan, I walk through a short clinical checklist with the patient:

| Checklist Item | Question |
|